ArticleThe oncologist2022
FDA Approval Summary: Revised Indication and Dosing Regimen for Ponatinib Based on the Results of the OPTIC Trial.
E Dianne Pulte et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
22 papers cite it
this papercites it